Loading
Nanoparticle-based Drug Delivery · Journal article
Amb Express · September 4, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a bench-level feasibility and characterization study of a nanoparticle formulation of Juniperus phoenicea extract, demonstrating in vitro antimicrobial synergy with amoxicillin and cefoxitin, and anticancer activity against an unspecified cell line. The work is exploratory and does not yet address in vivo efficacy, toxicology, or mechanism; the authors acknowledge that further in vivo studies and mechanistic investigation are needed.
In vitro antibacterial and anticancer screening with nanoparticle characterization. In vitro: multidrug-resistant bacterial panel (including Acinetobacter baumannii) and an unspecified cancer cell line; no human or animal subjects enrolled.. Intervention: Juniperus phoenicea L. ethanolic extract loaded into nanostructured lipid carriers (NLC); nanoparticles alone and in combination with Amoxicillin, Cefoxitin, and Fluorouracil.. Compared with: Ethyl acetate extract, crude ethanolic extract, and Fluorouracil monotherapy..
Ethanolic extract showed superior antibacterial activity versus ethyl acetate extract; Acinetobacter baumannii MIC = 12.5 µg/mL Nanoparticles enhanced antimicrobial potency (MIC = 6.25 µg/mL) and achieved complete eradication of A. baumannii after 16 hours Nanoparticle-antibiotic combinations (Amoxicillin, Cefoxitin) demonstrated synergistic effects
Cancer cell line type not specified; no toxicity or selectivity data reported. No in vivo efficacy, pharmacokinetics, or toxicology studies conducted.
This work does not yet support clinical application. It identifies a lead nanoformulation for further development but requires in vivo pharmacokinetics, toxicology, safety, efficacy in animal models, and mechanistic studies before any clinical translation can be contemplated.
In vitro study of plant extract nanoparticles showing antimicrobial and anticancer activity in cell culture with no animal or clinical data; requires in vivo validation before clinical relevance can be assessed.
As stated by the source record.
Quoted from the source exactly as published.
This work does not yet support clinical application. It identifies a lead nanoformulation for further development but requires in vivo pharmacokinetics, toxicology, safety, efficacy in animal models, and mechanistic studies before any clinical translation can be contemplated.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Abstract This study evaluates the antimicrobial properties of Juniperus phoenicea L. against multidrug-resistant microbes, highlighting potential synergistic effects of combining the J. phoenicea L. newly synthesized nanoparticles with conventional antibiotics and anticancer agents. Juniperus phoenicea L. ethanolic and ethyl acetate extracts were prepared. Antibacterial activity against a panel of multidrug-resistant microbes showed the ethanolic extract as superior to the ethyl acetate extract, with Acinetobacter baumannii being the most susceptible organism (minimum inhibitory MIC = 12.5 µg/mL). Phytochemical profiling of the ethanolic extract revealed predominant components, namely: Apigenin-7-glucoside, α-pinene, and Cedrol. Network pharmacology-based analysis suggested the potent effect of these compounds as anticancer and antibacterial agents. J. phoenicea L. nanoparticles were synthesized by a combined hot-melt dispersion and homogenization approach. Characterization yielded a zeta vesicle size of 98.6 nm, PDI 0.23, zeta potential + 48.5 mV, EE% 92.4%, and TEM size 76.2 nm. The nanoparticles markedly enhanced antibacterial activity (MIC = 6.25 µg/mL) with complete eradication of A. baumannii after 16 h. The combination with Amoxicillin and Cefoxitin showed synergistic effects. In anticancer assays, nanoparticles outperformed Fluorouracil, with IC 50 = 9.05 ± 0.49 µg/mL (≈ 8.7-fold higher anticancer potency than the crude extract). The Fluorouracil–nanoparticle combination further reduced IC 50 to 6.12 ± 0.41 µg/mL. Hence, it was concluded that J. phoenicea L. ethanolic extract exhibits potent antibacterial and anticancer properties and provides an effective nanoparticle precursor. Synergistic interactions with antibiotics and Fluorouracil suggest a multifaceted therapeutic strategy against infections and cancer, meriting further in vivo studies and mechanistic exploration.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.